Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is anticipated to announce its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $70.8710 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:00 AM ET.

Spyre Therapeutics (NASDAQ:SYRE) last announced its earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.08). On average, analysts expect Spyre Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Spyre Therapeutics Stock Up 2.8%

Shares of NASDAQ:SYRE opened at $73.00 on Thursday. Spyre Therapeutics has a twelve month low of $12.28 and a twelve month high of $76.00. The company has a market cap of $5.75 billion, a price-to-earnings ratio of -35.10 and a beta of 3.12. The business has a 50 day moving average price of $52.88 and a 200 day moving average price of $38.31.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SYRE shares. Wedbush boosted their price objective on Spyre Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft increased their target price on Spyre Therapeutics from $55.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. JonesTrading increased their target price on Spyre Therapeutics from $64.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, April 17th. Jefferies Financial Group raised their price target on Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Raymond James Financial initiated coverage on Spyre Therapeutics in a research note on Monday, April 13th. They issued a “strong-buy” rating and a $80.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $89.08.

Insider Activity

In other news, CEO Cameron Turtle sold 15,000 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $71.37, for a total value of $1,070,550.00. Following the sale, the chief executive officer directly owned 612,540 shares in the company, valued at $43,716,979.80. The trade was a 2.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 12,500 shares of Spyre Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $71.37, for a total value of $892,125.00. Following the completion of the sale, the chief financial officer directly owned 97,994 shares in the company, valued at approximately $6,993,831.78. This represents a 11.31% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 153,791 shares of company stock worth $9,805,860 over the last three months. Corporate insiders own 15.69% of the company’s stock.

Institutional Trading of Spyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SYRE. Russell Investments Group Ltd. raised its stake in Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after buying an additional 4,092 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Spyre Therapeutics during the fourth quarter worth approximately $74,000. Tower Research Capital LLC TRC grew its position in Spyre Therapeutics by 182.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock worth $86,000 after buying an additional 3,725 shares in the last quarter. Man Group plc acquired a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at $162,000. Finally, Martingale Asset Management L P acquired a new stake in shares of Spyre Therapeutics in the 4th quarter valued at $227,000. Institutional investors own 80.39% of the company’s stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.